Transcranial Magnetic Stimulation for Substance Addiction

N/A

Waitlist Available

Led By Ryan Carnahan, PharmD, MS

Research Sponsored by University of Iowa

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a new magnetic pulse treatment for people struggling with methamphetamine addiction. The treatment targets specific brain areas to help reduce cravings and improve self-control. It aims to see if this method can be more effective than typical treatments.

Eligible Conditions

Stimulant Addiction
Methamphetamine Addiction
Substance Addiction

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Retention in psychosocial treatment

Retention in the study

Secondary study objectives

Assessment of Recovery Capital

Brief Addiction Monitor Protective Factors Subscale

Brief Addiction Monitor Risk Factors Subscale

+18 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: MPFC firstExperimental Treatment1 Intervention

Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the medial prefrontal cortex stimulation first.

Group II: DPFC firstExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Transcranial Magnetic Stimulation

2017

Completed Phase 4

~730

Do I qualify?Apply below to find out